SkyGem Acquisition Limited has announced the closure of its unconditional mandatory cash offer to acquire all of the issued and to be issued shares in Allergy Therapeutics plc. The offer was made to shareholders who did not already hold shares in the company. Prior to the launch of the offer, SkyGem already held more than 50% of the voting rights of Allergy Therapeutics, making the offer unconditional from the outset. SkyGem received valid acceptances of the offer in respect of 247,935,057 shares, representing approximately 5.20% of the issued ordinary share capital of Allergy Therapeutics. Settlement of consideration to accepting shareholders will be made on or before 23 November 2023. Following settlement, SkyGem and its directors will hold 65.10% of the enlarged share capital of Allergy Therapeutics.